Seeking Alpha

Galena Biopharma higher on NeuVax deal with Dr. Reddy's

  • Galena Biopharma (GALE) adds to Monday's gains, rising 3.6% in premarket action.
  • The company says it has struck a strategic development and commercialization deal with Dr. Reddy's Laboratories (RDY) for NeuVax in India.
  • Details are sparse at this juncture.
  • GALE CEO Mark Ahn says the partnership "is consistent with [GALE's] strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy." (PR)
Comments (1)
  • Pelion
    , contributor
    Comments (41) | Send Message
     
    >Details are sparse at this juncture.

     

    Actually details are non-existent at this juncture and no 8K to view either.

     

    Includes this line: "Licensing and development terms contracted conditioned upon agreement on ancillary activities."

     

    Perhaps GALE should have waited for the "ancillary activities" to be finished before issuing a PR with no term details.
    14 Jan, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|